Sartorius Vz: JPMorgan expects an outperformance of the Q3 forecast – AI labs open up the next growth opportunity
Reading Time: 2 minutes
At Sartorius Vz., short-term better operational expectations meet a long-term exciting AI story. JPMorgan confirms its positive rating of overweight with a price target of €295. Sartorius and its subsidiary Sartorius Stedim Biotech are expected to slightly exceed market expectations in the third quarter. JPMorgan anticipates reassuring signals Sartorius confirmed a currency-adjusted revenue growth of 5 to 9% for 2026 after the first half of the year. Bioprocess Solutions is expected to grow by 6 to 10%, while Lab Products & Services is...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
